Target antibody makers Smaller biotech with strong focus on antibody development and characterization presents an opportunity to position SKi Pro as a fast, label-free kinetic analysis tool for lead optimization, epitope mapping and affinity maturation in therapeutic antibody programs.

Global collaboration potential Existing press mentions of partnerships with Tokyo University, Biosys Technologies and St. Marianna University indicate openness to academic and collaborative R&D models, suggesting potential for joint studies, pilot programs, or sponsored research using porous silicon biosensors.

High-value applications SKi Pro enables measurement of ultra-high affinity interactions and kinetic parameters across proteins, peptides, nucleic acids, and small molecules, aligning with secondary screening and in-depth characterization needs in drug discovery pipelines.

Strategic market fit With revenue in the lower mid single digits and a small team, there is a need for scalable, service-light offerings or partnerships with CROs and distributors to accelerate adoption in niche biomolecular interaction analysis markets.

Technology differentiation Porous silicon based, label-free analysis provides a unique value proposition for rapid KD and on/off rate measurements, suggesting competitive advantage against larger rivals through speed, sensitivity, and potential lower operating costs.